Cardiogenic ShockBEAT-SHOCKNCT07643610
BEAT-SHOCK Registry
An observational study of Cardiogenic Shock and Myocardial Infarction (MI), run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiogenic Shock, Myocardial Infarction (MI), Fulminant Myocarditis
- What is being tested?
- no internvention
- How many people
- 8,000 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Oct 2025to 1 Oct 2035
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients who are treated at the University Hospital Basel and are diagnosed with cardiogenic shock, irrespective of underlying etiology or therapeutic strategy. The registry includes a wide range of cardiogenic shock etiologies, including: * Myocardial infarction (MI) * Fulminant myocarditis * Acute decompensated heart failure * Severe valvular disease * Post-cardiotomy or perioperative cardiogenic shock
Who may be able to join
None listed.
Who cannot join
- Age <18 years
- Refusal to provide informed consent by the patient or their legally authorized representative
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
University Hospital Basel
Basel, Canton of Basel-City, 4031
Jasper Boeddinghaus, PD Dr. med., 0041613287897, jasper.boeddinghaus@usb.ch
Gregor Leibundgut, Prof. Dr. med., gregor.leibundgut@usb.ch
About this study
Official title: BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry
This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.
- Conditions
- Cardiogenic Shock, Myocardial Infarction (MI), Fulminant Myocarditis, Acute Decompensated Heart Failure, Severe Valvular Disease, Post-cardiotomy
- Being tested
- no internvention
- Keywords
- cardiogenic shock, Myocardial infarction (MI), Fulminant myocarditis, Acute decompensated heart failure, Severe valvular disease, Post-cardiotomy or perioperative cardiogenic shock, wide range of cardiogenic shock etiologies
- Medical subject headings
- Shock, Cardiogenic, Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
no internventionOther
This is a health data registry.
What is being measured
The primary outcome is the main question the study is designed to answer.
In-Hospital all-cause mortality occurring before discharge from the participating study centre
In-hospital all-cause mortality is defined as death occurring before discharge from the participating study centre. Deaths occurring after transfer to an external hospital are not counted as in-hospital deaths, but are captured through follow-up for 30-day and 90-day mortality.
Measured: 10 years
Secondary outcomes (3)
30-day and 90-day all-cause Mortality
30-day and 90-day all-cause mortality occuring after discharge from the participating study centre.
Measured: 30, 90 days
Need for organ support at any time during hospitalization
The need for organ support at any time during hospitalization (including renal replacement therapy, mechanical circulation support irrespective of type, and vasoactive or inotropic therapy)
Measured: 30, 60, 360 days
Acute kidney injury (AKI) within 36 hours after index diagnosis of cardiogenic shock/index presentation
Occurence of AKI (defined as an increase in serum creatinine of at least 26 µmol/L (0.3 mg/dL)
Measured: Within 36 hours after index diagnosis of cardiogenic shock/ index presentation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2026
- Study start1 Oct 2025
- Primary completion1 Oct 2035 (estimated)
- Study completion1 Oct 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiogenic ShockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 8,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07643610
- Sponsor's protocol ID
- BEAT SHOCK
- Acronym
- BEAT-SHOCK
- Status last verified
- Jun 2026
- First submitted
- 29 May 2026
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Not necessary, only data registry.
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry
- ClinicalTrials.gov ID
- NCT07643610
- Acronym / sponsor ID
- BEAT-SHOCK / BEAT SHOCK
- Conditions
- Cardiogenic Shock, Myocardial Infarction (MI), Fulminant Myocarditis, Acute Decompensated Heart Failure, Severe Valvular Disease, Post-cardiotomy
- Keywords
- cardiogenic shock, Myocardial infarction (MI), Fulminant myocarditis, Acute decompensated heart failure, Severe valvular disease, Post-cardiotomy or perioperative cardiogenic shock, wide range of cardiogenic shock etiologies
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 8,000 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 1 Oct 2035 (estimated)
- Study completion
- 1 Oct 2035 (estimated)
- First posted
- 11 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients who are treated at the University Hospital Basel and are diagnosed with cardiogenic shock, irrespective of underlying etiology or therapeutic strategy. The registry includes a wide range of cardiogenic shock etiologies, including: * Myocardial infarction (MI) * Fulminant myocarditis * Acute decompensated heart failure * Severe valvular disease * Post-cardiotomy or perioperative cardiogenic shock
Key inclusion criteria (0 listed)
Key exclusion criteria (2 listed)
- Age <18 years
- Refusal to provide informed consent by the patient or their legally authorized representative
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| no internventionThis is a health data registry. | Other | – |
Primary outcome
In-Hospital all-cause mortality occurring before discharge from the participating study centre
Time frame: 10 years
In-hospital all-cause mortality is defined as death occurring before discharge from the participating study centre. Deaths occurring after transfer to an external hospital are not counted as in-hospital deaths, but are captured through follow-up for 30-day and 90-day mortality.
3 secondary outcomes
30-day and 90-day all-cause Mortality
Time frame: 30, 90 days
Need for organ support at any time during hospitalization
Time frame: 30, 60, 360 days
Acute kidney injury (AKI) within 36 hours after index diagnosis of cardiogenic shock/index presentation
Time frame: Within 36 hours after index diagnosis of cardiogenic shock/ index presentation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Individual participant dataSharing planned: Undecided. Not necessary, only data registry.
Related trials for Cardiogenic Shock
RecruitingObservational study
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
Heart Failure, Muscle Atrophy
Recruiting
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
Cardiogenic Shock, Acute Myocardial Infarction of Inferior Wall
RecruitingObservational study
Factors Influencing Outcomes in ECMO and Impella Patients: Metabolic and Thyroid Hormone Dynamics
Cardiogenic Shock, Euthyroid Sick Syndrome
RecruitingObservational study
CytOSorb TreatMent Of Critically Ill PatientS Registry
Septic Shock, Acute Respiratory Distress Syndrome
Recruiting
Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock
Cardiogenic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiogenic Shock and Myocardial Infarction (MI), run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jasper Boeddinghaus, PD Dr. med. (0041613287897, jasper.boeddinghaus@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-Hospital all-cause mortality occurring before discharge from the participating study centre (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.